X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (78) 78
pulmonary hypertension (70) 70
female (67) 67
male (63) 63
middle aged (58) 58
respiratory system (57) 57
adult (50) 50
index medicus (48) 48
hypertension, pulmonary - physiopathology (38) 38
hypertension, pulmonary - drug therapy (36) 36
survival (35) 35
aged (34) 34
cardiac & cardiovascular systems (34) 34
transplantation (29) 29
pulmonary arterial hypertension (28) 28
abridged index medicus (26) 26
follow-up studies (24) 24
treatment outcome (24) 24
adolescent (22) 22
care and treatment (22) 22
diagnosis (22) 22
double-blind method (22) 22
drug therapy (22) 22
critical care medicine (21) 21
research (21) 21
therapy (21) 21
hypertension (19) 19
prognosis (19) 19
pulmonary/respiratory (19) 19
surgery (19) 19
analysis (18) 18
disease (18) 18
hypertension, pulmonary - mortality (18) 18
antihypertensive agents - therapeutic use (17) 17
bosentan (16) 16
risk factors (16) 16
time factors (16) 16
lung transplantation (15) 15
medical colleges (15) 15
registries (15) 15
endothelin receptor antagonists (13) 13
prospective studies (13) 13
usage (13) 13
cardiology and cardiovascular medicine (12) 12
hemodynamics (12) 12
retrospective studies (12) 12
antihypertensive agents - administration & dosage (11) 11
clinical trials (11) 11
familial primary pulmonary hypertension (11) 11
hypertension, pulmonary - diagnosis (11) 11
survival rate (11) 11
transplantation of organs, tissues, etc (11) 11
united states - epidemiology (11) 11
ambrisentan (10) 10
continuous intravenous epoprostenol (10) 10
dose-response relationship, drug (10) 10
double-blind (10) 10
endothelin (10) 10
hypertension, pulmonary - etiology (10) 10
lungs (10) 10
medicine, general & internal (10) 10
mortality (10) 10
prostacyclin (10) 10
drug therapy, combination (9) 9
epoprostenol - administration & dosage (9) 9
hemodynamics - physiology (9) 9
registry (9) 9
sulfonamides - therapeutic use (9) 9
administration, oral (8) 8
antihypertensive agents - adverse effects (8) 8
arterial-hypertension (8) 8
combination therapy (8) 8
dosage and administration (8) 8
heart-failure (8) 8
patient outcomes (8) 8
pulmonary arteries (8) 8
respiratory tract diseases (8) 8
sildenafil (8) 8
sitaxsentan (8) 8
walking - physiology (8) 8
brain natriuretic peptide (7) 7
disease progression (7) 7
epoprostenol - adverse effects (7) 7
exercise (7) 7
exercise test (7) 7
exercise tolerance (7) 7
exercise tolerance - drug effects (7) 7
health aspects (7) 7
heart (7) 7
hemodynamics - drug effects (7) 7
hypertension, pulmonary (7) 7
hypertension, pulmonary - epidemiology (7) 7
hypertension, pulmonary - therapy (7) 7
management (7) 7
prostacyclin analog (7) 7
pulmonary (7) 7
respiratory agents (7) 7
reveal (7) 7
tadalafil (7) 7
young adult (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Chest, ISSN 0012-3692, 10/2018, Volume 154, Issue 4, pp. 1021A - 1022A
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 1, pp. S67 - S77
Journal Article
Chest, ISSN 0012-3692, 2015, Volume 148, Issue 4, pp. 939A - 939B
Journal Article
Chest, ISSN 0012-3692, 09/2011, Volume 140, Issue 3, pp. 829 - 830
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2006, Volume 47, Issue 10, pp. 2049 - 2056
Journal Article
RESPIRATORY RESEARCH, ISSN 1465-993X, 09/2019, Volume 20, Issue 1, pp. 208 - 10
Background Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naive participants with... 
DOUBLE-BLIND | SELEXIPAG | Combination therapy | RESPIRATORY SYSTEM | Research-clinical | Pulmonary hypertension | Hypertension | Confidence intervals | Therapy | Clinical trials | Risk analysis | Patients | Subgroups | Research
Journal Article
Chest, ISSN 0012-3692, 2015, Volume 148, Issue 4, pp. 937A - 937B
Journal Article
Methodist DeBakey Cardiovascular Journal, ISSN 1947-6094, 2016, Volume 12, Issue 4 Suppl, pp. 10 - 13
Pulmonary hypertension (PH) is a complication and marker of disease severity in many parenchymal lung diseases. It also is a frequent complication of portal... 
parenchymal lung disease | pulmonary hypertension | Supplement | end-stage renal disease | COPD
Journal Article
Journal Article